What is Immunome's stock-based comp?

Immunome (IMNM) reported stock-based comp of $7.95M in Q1 2026.

How has Immunome's stock-based comp changed year-over-year?

Immunome's stock-based comp increased by 39.5% year-over-year, from $5.7M to $7.95M.

What is the long-term trend for Immunome's stock-based comp?

Over 4 years (2021 to 2025), Immunome's stock-based comp has grown at a 65.2% compound annual growth rate (CAGR), from $3.45M to $25.69M.

What does stock-based comp mean?

Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.

Immunome IMNM Stock-Based Comp

Stock-Based Comp at other companies

PfizerPFE

$272M+60.0%

Arcus BiosciencesRCUS

$19M+18.8%

Nuvation BioNUVB

$9.03M+15.0%

SELLAS Life Sciences Group, Inc.SLS

$798K+58.0%

ArriVent BioPharma, Inc.AVBP

$5.49M+142%

IDEAYA Biosciences, Inc.IDYA

$14.54M+42.0%

Other financials

Income statement

See full

Revenue--100%

Operating income-$59.3M-32.9%

Net income-$53.8M-29.3%

EPS (diluted)-$0.48+7.7%

Balance sheet

See full

Cash & equivalents$582.7M+126%

Total debt$3.7M-22.6%

Total equity$588.7M+91.7%

Total assets$619.8M+80.9%

Cash flow

See full

Operating cash flow-$58.6M-10.5%

CapEx$3.0M-18.1%

Free cash flow-$61.6M-8.7%

Valuation

See full

Market cap$2.19B+323%

Enterprise value$1.61B+470%

P/S545.2×+498×

Profitability

See full

Operating margin-5,947.9%-12,002pp

Net margin-5,593.8%-11,284pp

FCF margin-5,118.9%-8,601pp

Returns & leverage

See full

Return on equity-50.1%-10.8pp

Debt / equity0×0.0×

Current ratio21.7×+11.2×

Where this comes from

Reported directly by Immunome in its filing.

Tagged under the XBRL concept us-gaap:ShareBasedCompensation.

The official record: Immunome’s 10-Q, filed May 12, 2026, on SEC EDGAR. View the filing →

Ask your AI about Immunome's stock-based comp.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is Immunome's stock-based comp?: Immunome (IMNM) reported stock-based comp of $7.95M in Q1 2026.
How has Immunome's stock-based comp changed year-over-year?: Immunome's stock-based comp increased by 39.5% year-over-year, from $5.7M to $7.95M.
What is the long-term trend for Immunome's stock-based comp?: Over 4 years (2021 to 2025), Immunome's stock-based comp has grown at a 65.2% compound annual growth rate (CAGR), from $3.45M to $25.69M.
What does stock-based comp mean?: Total non-cash stock-based compensation expense for equity awards (RSUs, options, ESPP), added back to net income in cash flow reconciliation.